Title 02 Exploring the current advances in the management of metastatic NSCLC patients with Immunotherapy_dr. Anna Febriani, Sp.P(K), FAPSR ✅

Exploring the Current Advances in the Management of Metastatic NSCLC patients with Immunotherapy ANNA FEBRIANI Divisi Onkologi Toraks Pulmonologi Dan Kedokteran Respirasi FK UA – RSUD Dr Soetomo Surabaya
For Healthcare Professional Only Copyright 2023 PT MSD Indonesia., a subsidiary of Merck & Co., Inc. Rahway. NJ, USA. All rights reserved. PT MSD Indonesia. Wisma 46 Building 27th Fl. Jl. Jend. Sudirman No.Kav. 1, RT.10/RW.11, Karet Tengsin, Kecamatan Tanah Abang, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta 10220 Tel. +62 21 5789 7000 https://www.msd-indonesia.com/ Doc. No: ID-LAM-00109 Exp.Date : Dec/2025 Any report or enquiry related MSD Product Adverse Event, Product Quality Complaint, and etc. please Email: [email protected] Before ini)a)ng therapy, please consult the full Prescribing Informa)on. MSD does not recommend the use of any product in any different manner than as described in the Prescribing Informa:on.
OUTLINE • Background : Overview of Lung Cancer • Lung Cancer and Immune System • Immuno Oncology for Cancer Treatment • Pembrolizumab Landmark Trial : focus on Keynote 189 update • Take Home Message
Overview of Lung Cancer